| Stereochemistry | UNKNOWN |
| Molecular Formula | C18H36Cl2N4O2.2Cl |
| Molecular Weight | 482.316 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].OC(CCl)CN1CC[N+]2(CC1)CC[N+]3(CCN(CC(O)CCl)CC3)CC2
InChI
InChIKey=QZJPEEOEZVHUAE-UHFFFAOYSA-L
InChI=1S/C18H36Cl2N4O2.2ClH/c19-13-17(25)15-21-1-5-23(6-2-21)9-11-24(12-10-23)7-3-22(4-8-24)16-18(26)14-20;;/h17-18,25-26H,1-16H2;2*1H/q+2;;/p-2
Prospidium is a diazoniadispiro(5.2.5.2)hexadecane derivative patented by All-Union Scientific-Research Chemical-Pharmaceutical Institute as an antitumor agent that does not inhibit hematopoiesis. In preclinical models, The injection of Prospidium to thyroidectomized and hypophysectomized rats inhibited tumor growth to a greater extent than in intact rats. Larynx and lung cancer, lymphogranulomatosis, leucosis, etc. can be successfully treated with Prospidium at doses of 60-120 mg daily.
Approval Year
PubMed
Patents
ACTIVE MOIETY
SUBSTANCE RECORD
